Meeting
2017 Palliative and Supportive Care in Oncology Symposium
Risk of health-related quality of life events from pain and fatigue among patients with hormone receptor-positive HER-2 negative metastatic breast cancer treated with CDK 4/6 inhibitor.
Authors
Myat M. Han
University of Texas MD Anderson Cancer Center, Houston, TX
Myat M. Han, Kyaw Zin Thein, Myo Zaw, Aung Tun, Paul D'Cunha, Fred L. Hardwicke, Catherine Jones
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Integration and Delivery of Palliative and Supportive Care,Communication and Shared Decision Making,Symptom Biology, Assessment, and Management,Models of Care
Sub Track
Symptom Biology, Assessment, and Management
Citation
J Clin Oncol 35, 2017 (suppl 31S; abstract 215)
DOI
10.1200/JCO.2017.35.31_suppl.215
Abstract #
215
Poster Bd #
K7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.
First Author: Binghe Xu
Poster
2020 ASCO Virtual Scientific Program
Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.
First Author: Sara M. Tolaney
Poster
2022 ASCO Annual Meeting
postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy.
First Author: Kevin Kalinsky
Poster
2022 ASCO Annual Meeting
Post-recurrence survival in asymptomatic compared with symptomatic metastatic breast cancer: A multicenter retrospective study.
First Author: Sayaka Kuba